Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease

Psychopharmacology

Volumn 142, Issue 4, 1999, Pages 334-342

  Potter, Alexandra ^a   Corwin, June ^b   Lang, Jason ^a   Piasecki, Melissa ^a   Lenox, Robert ^c   Newhouse, Paul A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ABT 418; Alzheimer's disease; Learning; Memory; Novel nicotinic agonist

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; NICOTINIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; SPATIAL DISCRIMINATION; TRANSDERMAL DRUG ADMINISTRATION; VERBAL MEMORY;

AGED; ALZHEIMER DISEASE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; ISOXAZOLES; LEARNING; MALE; MEMORY; MIDDLE AGED; NICOTINIC AGONISTS; PROLACTIN; PSYCHOMOTOR PERFORMANCE; PYRROLIDINES;

EID: 0032953838     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050897     Document Type: Article

References (46)

1. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raskiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, Wasicak JT, Williams M (1994) (s)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J Pharmacol Exp Ther 270:310-318
2. Arneric SP, Sullivan JP, Williams M (1995) Neuronal nicotinic receptors: novel targets for central nervous system therapeutics. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 95-110
3. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541
4. Baddeley A (1988) Cognitive psychology and human memory. Trends Neurol Sci 11:176-181
5. Blennow K, Cowburn RF (1996) The neurochemisty of Alzheimer's disease. Acta Neurol Scand [Suppl] 168:77-86
6. Buschke H, Fuld P (1974) Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019-1025
7. Corwin J, Peselow E, Fieve R, Rotrosen J (1987) Memory in untreated depression: severity and task requirement effects. Presented at 26th Annual Meeting, American College of Neuropsychopharmacology, December, San Juan, PR
8. Decker MW, Majchrzak MJ, Anderson DJ (1992) Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res 572:281-285
9. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJB, Giardina WJ, Williams M, Arneric SP (1994) ABT 418: a novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. in vivo characterization. J Pharmacol Exp Ther 270:319-328
10. Elrod K, Buccafusco JJ, Jackson WJ (1988) Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43:277-287
11. Flynn DD, Mash DC (1986) Characterization of L-[3H] nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 47: 1948-1954
12. Folstein MF, Folstein SE, McHugh PR (1975) "The Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
13. Giacobini E (1990) Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurosci Res 27:548-560
14. Gotti C, Fornasari D, Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53:199-237
15. Heishman SJ, Taylor RC, Henningfield JE (1994) Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 2:345-395
16. Higgins ST, Woodward BM, Henningfield JE (1989): Effects of atropine on the repeated acquisition and performance of response sequences in humans. J Exp Anal Behav 51:5-15
17. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology 108:485-494
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA workshop. Neurology 34: 939-944
19. Newhouse PA (1990) Cholinergic drug studies in dementia and depression. Adv Exp Med Biol 282:65-76
20. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171-175
21. Newhouse PA, Belenky GL, Thomas M, Thorne D, Sing HC, Fertig J (1989) The effects of d-amphetamine on arousal, cognition and mood after prolonged total sleep deprivation. Neuropsychopharmacology 2:153-164
22. Newhouse PA, Sunderland T, Narang PK, Mellow AM, Fertig JB, Lawlor BA, Murphy DL (1990) Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in non-smoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 15:471-484
23. Newhouse PA, Potter A, Corwin J, Lenox R (1992) Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108:480-484
24. Newhouse PA, Potter A, Lenox RH (1993) Effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med Chem Res 2:628-642
25. Newhouse PA, Potter A, Corwin J, Lenox RH (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93-107
26. Newhouse PA, Potter A, Corwin J, Lenox RH (1995) Acute cognitive effects of nicotine in Alzheimer's and Parkinson's disease. Presented at 34th Annual Meeting, American College of Neuropsychopharmacology, San Juan PR, Dec 11-15, 1995
27. Newhouse PA, Potter A, Levin E (1997) Nicotinic system involvement in Alzheimer's and Parkinson's diseases: implications for therapeutics. Drugs Aging 11:206-228
28. Nelson JM, Goldstein L (1972) Improvement of performance on an attention task with chronic nicotine treatment in rats. Psychopharmacologia 26:347-360
29. Nordberg A (1994) Human nicotinic receptors - their role in aging and dementia. Neurochem Int 25:93-97
30. Nordberg A, Bergh C (1985) Effect of nicoine on passive avoidance behavior and motoric activity in mice. Acta Pharmacol Toxicol 54:337-341
31. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
32. Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 4:2745-2752
33. Perry RH, Perry EK, Smith CJ, Xuereb JH, Irving D, Whitford CA, Candy JM, Cross AJ (1987) Cortical neuropathological substrates of Alzheimer's and Parkinson's diseases. J Neural Transm Suppl 24:131-136
34. Porchet HC, Benowitz, NL, Sheiner LB (1988) Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 244:231-236
35. Reisberg B, Ferris SH, DeLean MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139:136-139
36. Robbins TW, Giardini V, Jones GH, Reading P, Sahakian B (1990) Effects of dopamine depletion from the caudate-putanen and nucleus accumbens septi on the acquisition and performance of a conditional discrimination task. Behav Brain Res 38:243-261
37. Sahakian BJ, Coull JT (1994) Nicotine and THA: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31:80-88
38. Sebree T, Grebb JA, Kittle C, Kashkin KB (1993) A phase I, single-, rising dose study of A-81418, a novel cholinergic channel activator (CHCA). Presented at 32nd Annual Meeting American College of Neuropsychopharmacology, December 13-17, Honolulu, HI
39. Snodgrass J, Corwin J (1988) Pragmatics of recognition memory: application to dementia and amnesia. J Exp Psychol [Gen] 117:34-50
40. Sunderland T, Tariot PN, Newhouse PA (1989) Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatrie populations. Brain Res Rev 13:371-389
41. Thompson D (1973) Repeated acquisition as a behavioral base line for studying drug effects. J Pharmacol Exp Ther 184:506-514
42. Vitaliano PP (1982) Parametric statistical analysis of repeated measures experiments. Psychoneuroendocrinology 7:3-13
43. Warburton DM, Rusted JM (1993) Cholinergic control of cognitive resources. Neuropsychobiology 28:43-46
44. Wesnes K, Warburton D (1983) Smoking, nicotine, and human performance. Pharmacol Ther 21:189-208
45. Whitehouse PJ, Martino AM, Antuona PG, Lowenstein PR, Coyle JT, Price DL, Kellar KJ (1986) Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 37:146-151
46. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995) Nicotine patches in Alzheimer's disease: pilot study on learning, memeory, and safety. Pharmacol Biochem Behav 51:509-514